De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Jazz Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Jazz Pharmaceuticals' is Bruce Cozadd, benoemd in Jan2003, heeft een ambtstermijn van 21.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.34M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.51% van de aandelen van het bedrijf, ter waarde $ 35.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 11.4 jaar.
Belangrijke informatie
Bruce Cozadd
Algemeen directeur
US$15.3m
Totale compensatie
| Percentage CEO-salaris | 7.8% |
| Dienstverband CEO | 21.8yrs |
| Eigendom CEO | 0.5% |
| Management gemiddelde ambtstermijn | 5.1yrs |
| Gemiddelde ambtstermijn bestuur | 11.4yrs |
Recente managementupdates
Recent updates
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25
Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market
Aug 24Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy
Aug 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$395m |
| Mar 31 2024 | n/a | n/a | US$331m |
| Dec 31 2023 | US$15m | US$1m | US$415m |
| Sep 30 2023 | n/a | n/a | US$80m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | -US$156m |
| Dec 31 2022 | US$17m | US$1m | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$52m |
| Mar 31 2022 | n/a | n/a | -US$450m |
| Dec 31 2021 | US$16m | US$1m | -US$330m |
| Sep 30 2021 | n/a | n/a | -US$161m |
| Jun 30 2021 | n/a | n/a | US$40m |
| Mar 31 2021 | n/a | n/a | US$518m |
| Dec 31 2020 | US$13m | US$1m | US$239m |
| Sep 30 2020 | n/a | n/a | US$179m |
| Jun 30 2020 | n/a | n/a | US$133m |
| Mar 31 2020 | n/a | n/a | US$280m |
| Dec 31 2019 | US$15m | US$1m | US$523m |
| Sep 30 2019 | n/a | n/a | US$609m |
| Jun 30 2019 | n/a | n/a | US$656m |
| Mar 31 2019 | n/a | n/a | US$486m |
| Dec 31 2018 | US$11m | US$979k | US$447m |
| Sep 30 2018 | n/a | n/a | US$520m |
| Jun 30 2018 | n/a | n/a | US$434m |
| Mar 31 2018 | n/a | n/a | US$447m |
| Dec 31 2017 | US$10m | US$950k | US$488m |
Compensatie versus markt: De totale vergoeding ($USD 15.34M ) Bruce } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.13M ).
Compensatie versus inkomsten: De vergoeding van Bruce is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Bruce Cozadd (60 yo)
21.8yrs
Tenure
US$15,341,235
Compensatie
Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 21.8yrs | US$15.34m | 0.51% $ 34.7m | |
| President & COO | less than a year | US$5.43m | 0.027% $ 1.8m | |
| Senior VP & Chief Accounting Officer | 5.2yrs | US$1.40m | geen gegevens | |
| Executive VP & Chief Legal Officer | 5.3yrs | US$3.88m | 0.018% $ 1.2m | |
| Executive VP | 5.4yrs | US$4.98m | 0.046% $ 3.1m | |
| Executive VP & CFO | less than a year | geen gegevens | 0.019% $ 1.3m | |
| VP & Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief People Officer | 5.9yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Sleep & CNS Medicine | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Commercial OfficerChief Commercial Officer | 4.6yrs | geen gegevens | 0.010% $ 702.5k | |
| Senior Vice President of Corporate Strategy | 5.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Technical Operations | 1.2yrs | geen gegevens | 0.0021% $ 140.2k |
5.1yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van JAZZ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 21.8yrs | US$15.34m | 0.51% $ 34.7m | |
| Independent Director | 20.8yrs | US$513.77k | 0.045% $ 3.0m | |
| Independent Director | 12.8yrs | US$531.27k | 1.89% $ 128.3m | |
| Independent Director | 11.4yrs | US$533.77k | 0.020% $ 1.3m | |
| Independent Director | 15.3yrs | US$526.27k | 0.034% $ 2.3m | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Lead Independent Director | 14.4yrs | US$571.27k | 0.015% $ 983.0k | |
| Independent Non-Executive Director | 3.8yrs | US$533.77k | 0.0088% $ 592.8k | |
| Independent Director | less than a year | geen gegevens | 0.0024% $ 164.6k | |
| Independent Director | 11.4yrs | US$543.77k | 0.025% $ 1.7m | |
| Independent Non-Executive Director | 3.8yrs | US$521.27k | 0.0088% $ 592.8k | |
| Independent Director | 5.7yrs | US$523.77k | 0.018% $ 1.2m |
11.4yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van JAZZ zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.4 jaar).